Grow Your Wealth
with Mutual Funds
Nippon India Pharma Fund Direct-idcw
Equity
Mid Cap
Very High Risk
Latest AUM
₹ 7,898.2 Cr.
NAV as on 27 jul, 2026
₹ 173.45
+20.58%
3 years annulised
This Fund
Fund Details
Fund Names
Nippon India Pharma Fund Direct-idcw
Lock In
No Lock-in
SIP Minimum Investment amount
₹100
SWP Minimum Investment amount
₹500
STP Minimum Investment amount
₹100
Risk
Principal at very high risk
Category Average Annual Returns
6.04
Portfolio Composition Analysis
Equity
97.64%
Debt
0.01%
Cash
2.35%
Portfolio Updated on: 10 Jul, 2026
Sector Allocations
Equity
Healthcare
Portfolio Updated on: 27 jul, 2026
Top 10 Holdings
| Name | Sector | Instruments | Assets |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | Healthcare | Equity | 1.00% |
| Sun Pharmaceutical Industries Ltd | Healthcare | Equity | 1.00% |
| Sun Pharmaceutical Industries Ltd | Healthcare | Equity | 1.00% |
| Sun Pharmaceutical Industries Ltd | Healthcare | Equity | 13.55% |
| Sun Pharmaceutical Industries Ltd | Healthcare | Equity | 13.92% |
| Sun Pharmaceutical Industries Ltd | Healthcare | Equity | 13.08% |
| Sun Pharmaceutical Industries Ltd | Healthcare | Equity | 13.02% |
| Sun Pharmaceutical Industries Ltd | Healthcare | Equity | 12.67% |
| Sun Pharmaceutical Industries Ltd | Healthcare | Equity | 12.67% |
| Sun Pharmaceutical Industries Ltd | Healthcare | Equity | 12.67% |
Debt & Credit Risk Analysis
| Alpha | -0.08% |
| Beta | 0.91% |
| Sharpe Ratio | 1.02% |
| Standard Deviation | 15.72% |
Returns Analysis
| Tenure | Absolute | Annualised | Category Average |
|---|---|---|---|
| 3 Months | 9.15% | NA | 6.12% |
| 6 Months | 16.47% | NA | 12.92% |
| 9 Months | 10.58% | NA | 4.47% |
| 1 Year | 7.36% | 7.36% | 6.04% |
| 2 Years | 18.90% | 9.04% | 24.93% |
| 3 Years | 70.01% | 19.35% | 25.71% |
| 5 Years | 92.63% | 14.01% | 19.91% |
| 7 Years | 321.82% | 22.83% | NA |
| 10 Years | 338.11% | 15.92% | 12.78% |
Nippon India Pharma Fund Direct-idcw is one Equity mutual fund offered by Nippon India Mutual Fund. the fund aims Long term capital growth. Investment in equity and equity related Securities of pharma & other associated companies. It manages assets worth ₹7,898.2 crore as on Tue Mar 31, 2026. The expense ratio stands at 0.93%.
Sailesh Raj Bhan has experience Prior to joining Nippon India Mutual Fund, he has worked with Emkay Share & Stock Broker Pvt. Ltd, Shah & Sequeira Invst. Pvt. Ltd, ICFAI- Securities Research Center Analyst - Equity Research.
Top Performing Mutual Funds
growth is based on 1-month returns of the funds & Top fund are based on 3Y Returns
More Funds from Nippon India Mutual Fund
| Fund name | |||||||
|---|---|---|---|---|---|---|---|
| Nippon India Pharma Fund-growth | 7,898.2 | +2.37% | +8.92% | +15.97% | +6.41% | +18.28% | +12.99% |
| Nippon India Pharma Fund Direct-growth | 7,898.2 | +2.44% | +9.15% | +16.47% | +7.36% | +19.35% | +14.01% |
| Nippon India Pharma Fund Direct-growth | 7,898.2 | +2.44% | +9.15% | +16.47% | +7.36% | +19.35% | +14.01% |
| Nippon India Pharma Fund-idcw | 7,898.2 | +2.37% | +8.92% | +15.97% | +6.41% | +18.28% | +12.99% |
| Nippon India Nifty Pharma Etf-growth | 1,247.9 | +4.08% | +12.23% | +19.56% | +14.83% | +20.80% | +13.69% |
growth is based on 1-month returns of the funds
Top Mutual Funds
| Fund name | |||||||
|---|---|---|---|---|---|---|---|
| Nippon India Pharma Fund Direct-growth | 7,898.2 | +2.44% | +9.15% | +16.47% | +7.36% | +19.35% | +14.01% |
| Nippon India Pharma Fund-growth | 7,898.2 | +2.37% | +8.92% | +15.97% | +6.41% | +18.28% | +12.99% |
| Nippon India Pharma Fund Direct-growth | 7,898.2 | +2.44% | +9.15% | +16.47% | +7.36% | +19.35% | +14.01% |
| Nippon India Pharma Fund-idcw | 7,898.2 | +2.37% | +8.92% | +15.97% | +6.41% | +18.28% | +12.99% |
| ICICI Prudential Pharma Healthcare And Diagnostics (p.h.d) Fund-growth | 6,293.1 | +1.81% | +9.15% | +16.35% | +6.18% | +23.07% | +15.99% |
| ICICI Prudential Pharma Healthcare And Diagnostics (p.h.d) Fund Direct-growth | 6,293.1 | +1.88% | +9.37% | +16.82% | +7.07% | +24.11% | +17.02% |
| ICICI Prudential Pharma Healthcare And Diagnostics (p.h.d) Fund Direct-idcw | 6,293.1 | +1.88% | +9.37% | +16.82% | +7.07% | +24.11% | +17.02% |
| ICICI Prudential Pharma Healthcare And Diagnostics (p.h.d) Fund-idcw | 6,293.1 | +1.81% | +9.15% | +16.35% | +6.18% | +23.07% | +15.99% |
Top funds are based on Fund AUM
Top Equity Funds
| Fund name | ||||
|---|---|---|---|---|
| Sbi Healthcare Opportunities Fund Direct Plan-growth | ₹585.48 | +23.82% | +18.25% | — |
| Sbi Healthcare Opportunities Fund Direct Plan-growth | ₹585.48 | +23.82% | +18.25% | — |
| Sbi Healthcare Opportunities Fund Direct Plan-idcw | ₹406.78 | +23.82% | +18.25% | — |
| Sbi Healthcare Opportunities Fund Direct Plan-idcw | ₹406.78 | +23.82% | +18.25% | — |
| Icici Prudential Pharma Healthcare And Diagnostics (p.h.d) Fund Direct-growth | ₹47.15 | +24.11% | +17.02% | — |
| Icici Prudential Pharma Healthcare And Diagnostics (p.h.d) Fund Direct-idcw | ₹28.47 | +24.11% | +17.02% | — |
| Sbi Healthcare Opportunities Fund-growth | ₹506.05 | +22.55% | +17.02% | — |
| Sbi Healthcare Opportunities Fund-idcw | ₹318.78 | +22.55% | +17.02% | — |
| Mirae Asset Healthcare Fund Direct-growth | ₹50.72 | +23.36% | +16.17% | — |
| Mirae Asset Healthcare Fund Direct-idcw | ₹30.55 | +23.36% | +16.17% | — |
growth is based on 5Y returns of the funds
Historical NAV
| Date | NAV |
|---|---|
| 27 Jul 2026 | ₹173.45 |
| 24 Jul 2026 | ₹171.05 |
| 23 Jul 2026 | ₹171.43 |
| 22 Jul 2026 | ₹172.10 |
| 21 Jul 2026 | ₹174.94 |
| 20 Jul 2026 | ₹174.34 |
| 17 Jul 2026 | ₹172.52 |
| 16 Jul 2026 | ₹174.48 |
| 15 Jul 2026 | ₹174.08 |
| 14 Jul 2026 | ₹173.62 |
| 13 Jul 2026 | ₹172.52 |
| 10 Jul 2026 | ₹172.90 |
| 09 Jul 2026 | ₹172.31 |
| 08 Jul 2026 | ₹170.80 |
| 07 Jul 2026 | ₹172.74 |
| 06 Jul 2026 | ₹173.66 |
| 03 Jul 2026 | ₹173.46 |
| 02 Jul 2026 | ₹171.39 |
| 01 Jul 2026 | ₹170.63 |
| 30 Jun 2026 | ₹171.36 |
| 29 Jun 2026 | ₹170.12 |
| 25 Jun 2026 | ₹169.31 |
| 24 Jun 2026 | ₹169.63 |
| 23 Jun 2026 | ₹169.06 |
| 22 Jun 2026 | ₹168.19 |
| 19 Jun 2026 | ₹166.78 |
| 18 Jun 2026 | ₹165.79 |
| 17 Jun 2026 | ₹164.49 |
| 15 Jun 2026 | ₹164.81 |
| 12 Jun 2026 | ₹165.49 |
Portfolio Updated on: 28 Jul, 2026
Fund Growth & Size Analysis
+₹7,898.2 Cr
Since Launch
This Fund
Category Average
Compare Mutual funds
Nippon India Pharma Fund Direct-idcw Returns Comparison
Compare Nippon India Pharma Fund Direct-idcw with any MF,
EYF, stock or index
Jan 1, 2026 – Feb 1, 2026
Nippon India Pharma Fu....
No funds found for your search.
Nippon India Pharma Fund Direct-idcw FAQ'S
- Sharpe Ratio: 1.02%
- Standard Deviation: 15.72%
- Beta: 0.91%
- Alpha: -0.08%
Additional important ratios:
As of Tue Mar 31, 2026, the total assets managed under Nippon India Pharma Fund Direct-idcw stand at approximately ₹ 7,898.2 crore.
The Nippon India Pharma Fund Direct-idcw has delivered the following short-term performance:
- 3 Months Return: 9.15%
- 6 Months Return: 16.47%
The historical growth of the Nippon India Pharma Fund Direct-idcw is reflected through its CAGR returns:
- 3 Year CAGR: 19.35%
- 5 Year CAGR: 14.01%
- Return Since Launch: 17.64%
The portfolio of Nippon India Pharma Fund Direct-idcw is distributed across different asset classes as follows:
- Equity: 97.64%
- Debt Instruments: 0.01%
- Other Assets: 2.35%
The Nippon India Pharma Fund Direct-idcw is managed by Sailesh Raj Bhan, representing Nippon India Mutual Fund.
The Nippon India Pharma Fund Direct-idcw investments are allocated across market caps in the following manner:
- Large Cap Stocks: 1.00%
- Mid Cap Stocks: 1.00%
- Small Cap Stocks: 1.00%
Top stock holdings of Nippon India Pharma Fund Direct-idcw include:
- Sun Pharmaceutical Industries Ltd – represents 1.00% of the portfolio
- Sun Pharmaceutical Industries Ltd – represents 1.00% of the portfolio
- Sun Pharmaceutical Industries Ltd – represents 1.00% of the portfolio
- Sun Pharmaceutical Industries Ltd – represents 13.55% of the portfolio
- Sun Pharmaceutical Industries Ltd – represents 13.92% of the portfolio
- Sun Pharmaceutical Industries Ltd – represents 13.08% of the portfolio
- Sun Pharmaceutical Industries Ltd – represents 13.02% of the portfolio
- Sun Pharmaceutical Industries Ltd – represents 12.67% of the portfolio
- Sun Pharmaceutical Industries Ltd – represents 12.67% of the portfolio
- Sun Pharmaceutical Industries Ltd – represents 12.67% of the portfolio
Major sector exposures in Nippon India Pharma Fund Direct-idcw are:
- Healthcare – accounts for 996.17% of the portfolio
